血清RP11-731F5.2作为胃癌诊断和预后的无创生物标志物的测定

Determination of serum RP11-731F5.2 as a noninvasive biomarker for gastric cancer diagnosis and prognosis.

作者信息

Jing Rongrong, Liu Sinan, Jiang Yun, Zong Wei, Ju Shaoqing, Cui Ming

机构信息

Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China.

出版信息

Pathol Res Pract. 2020 Dec;216(12):153261. doi: 10.1016/j.prp.2020.153261. Epub 2020 Oct 21.

DOI:10.1016/j.prp.2020.153261

PMID:33176259

Abstract

BACKGROUND

Gastric cancer (GC) is one of malignant tumor with the highest incidence and mortality in the world. The long noncoding RNA (lncRNA) play an important role in GC. We aim to systematically evaluate the clinical values of lncRNA RP11-731F5.2 in GC.

METHODS

We evaluated the level of serum RP11-731F5.2 by the reverse transcription and quantitative real-time PCR. The study involved following aspects: (1) confirmation of the higher RP11-731F5.2 level in serum specimens of GC; (2) evaluation of efficacy monitoring value by the serum RP11-731F5.2 assay in GC; (3) evaluation of the prognostic value by the serum RP11-731F5.2 assay in GC.

RESULTS

The level of RP11-731F5.2 stably present in the serum of GC patients (median [interquartile range, IQR 25-75]: 1.495 [0.912-2.367]) was significantly higher than that in healthy controls (0.620 [0.400-1.222]) (P < 0.001). Combined with RP11-731F5.2, CEA and CA19-9, the area under the curve was the largest (0.84, 95 % confidence interval, 0.77-0.90), which can significantly improve the diagnostic efficacy of GC. Moreover, the level of serum RP11-731F5.2 in postoperative samples decreased significantly compared with the level of preoperative samples (2.415 [1.558-3.115] versus 2.007 [1.112-2.711], P = 0.029). There was difference in survival time between GC patients containing higher level of RP11-731F5.2 and those with lower level of RP11-731F5.2 (P = 0.048).

CONCLUSION

Our study suggested that circulating RP11-731F5.2 may be employed as a novel diagnostic, efficacy monitoring and prognostic biomarker for GC.

摘要

背景

胃癌（GC）是全球发病率和死亡率最高的恶性肿瘤之一。长链非编码RNA（lncRNA）在胃癌中发挥重要作用。我们旨在系统评估lncRNA RP11 - 731F5.2在胃癌中的临床价值。

方法

我们通过逆转录和定量实时PCR评估血清RP11 - 731F5.2水平。该研究涉及以下几个方面：（1）确认胃癌血清标本中RP11 - 731F5.2水平较高；（2）通过血清RP11 - 731F5.2检测评估胃癌疗效监测价值；（3）通过血清RP11 - 731F5.2检测评估胃癌预后价值。

结果

RP11 - 731F5.2水平稳定存在于胃癌患者血清中（中位数[四分位间距，IQR 25 - 75]：1.495[0.912 - 2.367]），显著高于健康对照（0.620[0.400 - 1.222]）（P < 0.001）。结合RP11 - 731F5.2、癌胚抗原（CEA）和糖类抗原19 - 9（CA19 - 9），曲线下面积最大（0.84，95%置信区间，0.77 - 0.90），可显著提高胃癌诊断效能。此外，术后样本中血清RP11 - 731F5.2水平较术前样本显著降低（2.415[1.558 - 3.115]对2.007[1.112 - 2.711]，P = 0.029）。RP11 - 731F5.2水平较高的胃癌患者与较低水平的患者生存时间存在差异（P = 0.048）。